Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholinergic markers in ALS spinal cord.

M L Berger1, M Veitl, S Malessa

  • 1Institute of Biochemical Pharmacology, University of Vienna, Austria.

Journal of the Neurological Sciences
|March 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of injectable trace minerals on humoral and cell-mediated immune responses to Bovine viral diarrhea virus, Bovine herpes virus 1 and Bovine respiratory syncytial virus following administration of a modified-live virus vaccine in dairy calves.

Veterinary immunology and immunopathology·2016
Same author

The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.

Neurobiology of disease·2012
Same author

Screening of 64 tryptamines at NMDA, 5-HT1A, and 5-HT2A receptors: a comparative binding and modeling study.

Current medicinal chemistry·2012
Same author

Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.

Neuroscience·2011
Same author

Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Neurochemistry international·2010
Same author

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.

Parkinsonism & related disorders·2008

Amyotrophic lateral sclerosis (ALS) shows significant loss of quinuclidinyl benzilate (QNB) binding sites in the spinal cord ventral horn. This reduction in muscarinic binding sites is a reliable marker for cholinergic dysfunction in ALS patients.

Area of Science:

  • Neuroscience
  • Neurology
  • Biochemistry

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons.
  • Cholinergic pathways, involving acetylcholine, play a role in motor function and are implicated in neurodegenerative processes.
  • Understanding cholinergic deficits in ALS is crucial for identifying disease markers and potential therapeutic targets.

Purpose of the Study:

  • To investigate the status of cholinergic markers, specifically muscarinic (quinuclidinyl benzilate, QNB) and choline uptake (hemicholinium-3, HC-3) binding sites, in the spinal cord of ALS patients.
  • To assess the activity of key cholinergic enzymes, choline acetyltransferase (ChAT) and acetylcholinesterase (AChE), in the affected spinal cord regions.
  • To determine the most reliable cholinergic marker for ALS pathology.

Related Experiment Videos

Main Methods:

  • Quantitative slice autoradiography was employed to measure QNB and HC-3 binding site densities.
  • Enzyme activity assays were performed to quantify ChAT and AChE levels.
  • Analysis was conducted on spinal cord tissue samples from 5-7 patients diagnosed with ALS and compared to control subjects.

Main Results:

  • A significant reduction in QNB binding sites was observed in the ventral horn of ALS patients, approximately 38% of control levels (P < 0.001).
  • HC-3 binding sites showed a moderate decrease, with levels around 76% of controls (P < 0.01).
  • Losses in ChAT and AChE enzyme activities were inconsistent across ALS patients.

Conclusions:

  • The marked loss of muscarinic QNB binding sites in the ventral horn is the most consistent and reliable cholinergic marker identified in ALS.
  • While other cholinergic markers are affected, the reduction in QNB binding provides a strong indicator of cholinergic system impairment in ALS.
  • These findings highlight the utility of muscarinic receptor binding analysis in understanding ALS pathophysiology.